Akebia Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AKBA Nasdaq 2834 https://akebia.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akebia Therapeutics Inc

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 1st, 2021 8:05 pm
Health Check: How Prudently Does Akebia Therapeutics (NASDAQ:AKBA) Use Debt? - Sep 6th, 2021 10:23 am
Akebia Therapeutics Announces September 2021 Investor Conference Schedule - Sep 1st, 2021 12:00 pm
Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript - Aug 5th, 2021 8:31 pm
Why Akebia Therapeutics Stock Is Soaring Today - Aug 5th, 2021 8:00 pm
Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates - Aug 5th, 2021 1:15 pm
Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - Aug 5th, 2021 11:58 am
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Jul 29th, 2021 7:05 pm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm - Jul 27th, 2021 10:15 pm
SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger - Jul 26th, 2021 5:47 pm
Akebia Therapeutics to Report Second Quarter 2021 Financial Results and Discuss Recent Business Highlights - Jul 26th, 2021 12:00 pm
Reflecting on Akebia Therapeutics' (NASDAQ:AKBA) Share Price Returns Over The Last Year - Jun 8th, 2021 5:20 am
Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise - Jun 4th, 2021 2:27 pm
Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021 - Jun 3rd, 2021 12:00 pm
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis - Jun 1st, 2021 10:00 am
Implied Volatility Surging for Akebia Therapeutics (AKBA) Stock Options - May 25th, 2021 12:10 pm
New Strong Sell Stocks for May 12th - May 12th, 2021 1:11 pm
Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates - May 10th, 2021 1:20 pm
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones - May 10th, 2021 12:00 pm
Akebia Therapeutics, Inc. to Host Earnings Call - May 10th, 2021 11:15 am